Stryker (NYSE:SYK) Releases FY 2026 Earnings Guidance

Stryker (NYSE:SYK) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 14.950-15.100 for the period, compared to the consensus estimate of 14.980. The company issued revenue guidance of -.

Stryker Trading Down 6.2%

NYSE SYK traded down $21.63 during mid-day trading on Friday, reaching $326.41. 4,535,844 shares of the stock were exchanged, compared to its average volume of 2,249,660. The stock has a market cap of $125.13 billion, a P/E ratio of 33.82, a P/E/G ratio of 2.23 and a beta of 0.77. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker has a one year low of $281.00 and a one year high of $401.99. The stock has a 50 day simple moving average of $317.28 and a 200-day simple moving average of $334.92.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 24.06%. The business had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter in the prior year, the firm posted $3.13 earnings per share. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts anticipate that Stryker will post 14.99 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 40.74%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on SYK shares. BMO Capital Markets began coverage on Stryker in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 target price for the company. Leerink Partners reduced their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Weiss Ratings cut shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 4th. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on shares of Stryker in a report on Friday, May 1st. Finally, Argus set a $370.00 price target on Stryker in a research report on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $387.88.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 323,264 shares of company stock valued at $100,659,489. Insiders own 4.60% of the company’s stock.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reported second-quarter revenue of $6.59 billion, up 9.4% year over year, while adjusted EPS of $3.69 exceeded consensus estimates. Organic sales growth reached 9%, supported by strong demand for orthopedic, spinal and other medical devices. Stryker beats quarterly estimates on strong demand for medical devices
• Positive Sentiment: Management said it has regained momentum following the cyber disruption and resumed share repurchases. Its full-year guidance calls for 8.3% to 9.3% organic sales growth and adjusted EPS of $14.95 to $15.10. Stryker expects 2026 organic sales growth and adjusted EPS
• Positive Sentiment: JPMorgan maintained an “overweight” rating, although it reduced its price target to $350. Truist raised its target to $340 while retaining a “hold” rating, and BTIG continues to rate the shares “buy.”
• Neutral Sentiment: The updated guidance was narrower but remained broadly close to prior expectations and analyst forecasts. This suggests operational stability, but not a major upside revision that could drive a stronger investor reaction.
• Neutral Sentiment: Analyst opinion remains generally constructive, with no recent sell ratings cited and a six-month median price target of $385, though target reductions indicate some caution regarding valuation or near-term upside.
• Negative Sentiment: The main pressure on SYK appears to be an expectations reset: despite the earnings beat, investors had anticipated a more substantial increase to full-year guidance after the cyberattack recovery. SYK falls despite Q2 earnings beat
• Negative Sentiment: Reported insider activity has been heavily weighted toward selling, with no purchases and substantial sales over the past six months. This may add to investor concerns about valuation and management confidence, although the trades do not necessarily reflect current operating performance.

Institutional Investors Weigh In On Stryker

Several hedge funds have recently added to or reduced their stakes in the stock. United Financial Planning Group LLC bought a new position in shares of Stryker during the 3rd quarter valued at $27,000. Atlas Capital Advisors Inc. bought a new stake in Stryker during the fourth quarter valued at about $27,000. Strive Asset Management LLC bought a new position in Stryker in the 3rd quarter worth approximately $30,000. Birchwood Financial Partners Inc. purchased a new position in Stryker during the fourth quarter valued at $35,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Stryker in the fourth quarter worth about $49,000. 77.09% of the stock is owned by institutional investors.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.